AIGH Capital Management LLC acquired a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission.
Plus Therapeutics Stock Performance
PSTV opened at $1.41 on Monday. The business has a 50 day moving average of $1.60 and a 200-day moving average of $1.81. Plus Therapeutics, Inc. has a 52 week low of $0.97 and a 52 week high of $3.21.
Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. Plus Therapeutics had a negative net margin of 240.15% and a negative return on equity of 805.57%. The business had revenue of $1.28 million for the quarter. As a group, analysts expect that Plus Therapeutics, Inc. will post -2.22 EPS for the current year.
Analysts Set New Price Targets
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Recommended Stories
- Five stocks we like better than Plus Therapeutics
- What Are Growth Stocks and Investing in Them
- Could Semtech Be the Next Big Thing in IoT and Smart Cities?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Medtronic Stock: Growth On Rise of the Cardiovascular Machines
- Trading Halts Explained
- Is Back-to-School Spending a Sign of Growing Consumer Confidence?
Want to see what other hedge funds are holding PSTV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report).
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.